Clinical trials: Heart Failure With Reduced Ejection Fraction
Heart Failure
Efficacy and Safety of Sacubitril/Valsartan in African American Patients With Heart Failure With Reduced Ejection Fraction
There is limited long-term evidence specific to AAs with HFrEF on sacubitril/valsartan therapy. Plasma NT-proBNP levels are lower in AA individuals as compared to Caucasian individuals in general.
- Trial name
- NCT05168787
- Testing
- sacubitril/valsartan
- Where
- United States
- Volunteers
- 6,558 people
- Sponsor
- Methodist Health System
Heart Failure With Reduced Ejection Fraction
Effects of 2-week Ketosis on the Heart's Ketone Body Consumption, Utilization, and Energetic Efficiency in Patients With Chronic Heart Failure
Heart Failure (HF) is a significant health concern, affecting around 1-2% of people in Western countries. The risk of developing HF during a lifetime is about 20%.
- Trial name
- KETO-CHF PET (NCT06398964)
- Testing
- 3-hydroxybutyrat
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aarhus University Hospital
Heart Failure With Reduced Ejection Fraction
PHARM Optimal-HF Pilot
The goal if this pilot randomized controlled trial is to determine the feasibility of conducting and guide the design of a definitive trial of a pharmacist-led, remotely-administered intervention to optimize medications for heart…
- Trial name
- NCT05623358
- Testing
- Pharmacist-led HFrEF medication optimization, Usual care
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University of British Columbia
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction
The purpose of this study was to assess the effect of LCZ696 at a target dose of 200 mg b.i.d. compared to enalapril 10 mg b.i.d., in addition to the background heart failure (HF) treatment, on delaying time to first occurrence…
- Trial name
- PARALLEL-HF (NCT02468232)
- Testing
- LCZ696, Enalapril
- Where
- 49 sites in Japan
- Volunteers
- 225 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic
Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure
Real-world evidence of the clinical course of patient symptoms following initiation of sacubitril/valsartan via PROs with a patient-centered study design will provide important evidence of potentially beneficial outcomes…
- Trial name
- PROVIDE-HF (NCT03387163)
- Testing
- Sacubitril/Valsartan
- Where
- United States
- Volunteers
- 402 people
- Sponsor
- Novartis Pharmaceuticals
Defibrillators, Implantable, Heart Failure With Reduced Ejection Fraction
Multi-centre Observational Registry on Patients With Implantable Devices Remotely Monitored
Multicentric, observational, retrospective registry including patients underwent implantable device implantation (pacemaker or ICD) for any indication in the period from 2009 to 2016, followed by remote monitoring.
- Conditions
- Defibrillators, Implantable, Heart Failure With Reduced Ejection Fraction, Arrythmia, Pacemaker
- Trial name
- IMPLANTED (NCT03061747)
- Testing
- Assesment of outcome of implantable device patients
- Where
- 6 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda Ospedaliera Cardinale G. Panico
Heart Failure With Preserved Ejection Fraction, Microvascular Angina
Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study
This is an observational study of Neuregulin-1 (NRG-1) plasma levels in patients with different forms of cardiovascular disease including microvascular angina (MVA), heart failure with preserved ejection fraction (HFpEF), as well…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Microvascular Angina, Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction
- Trial name
- NRG-1-CVDs (NCT04391491)
- Testing
- Neuregulin-1β level in plasma
- Where
- Russia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Heart Failure With Reduced Ejection Fraction
Demographic, Clinical, Biological, Treatment Characteristics and Cardiovascular Events of Patients With Heart Failure in Vietnam: a Multicenter Prospective Observational Study
Describe the clinical characteristics, paraclinical features, and treatment during hospitalization, as well as at 1, 3, and 12 months post-discharge, of heart failure patients at selected cardiovascular centers in Vietnam.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
- Trial name
- MCR-HF (NCT06516562)
- Testing
- Optimal treatment
- Where
- Vietnam
- Volunteers
- 2,500 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Heart Failure With Reduced Ejection Fraction
Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure
The Email Nudges to Improve GDMT (MRA) Adherence in Heart Failure (ENIGMA-HF) study is a pragmatic parallel-arm randomized control trial of a quality improvement (QI) intervention involving email nudges to cardiology clinic…
- Trial name
- ENIGMA-HF (NCT05806970)
- Testing
- Email Nudge
- Where
- United States
- Sponsor
- University of California, Los Angeles
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Heart Failure, Healthy Volunteer
Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients
To evaluate the safety and tolerability of ascending single (Part A) and ascending multiple (Part B) doses of AMG 986 in healthy adults and of ascending multiple oral doses of AMG 986 in heart failure patients (Part C).
- Trial name
- NCT03276728
- Testing
- AMG 986 IV, AMG 986 PO
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Amgen
Heart Failure
Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
Study hypothesis: Comparing the effect of digoxin and ivabradine in chronic heart failure patients with a left ventricular ejection of 35% or lower and sinus rhythm with heart rate 70 beats per minute or higher, and who are…
- Trial name
- DIVA-REF (NCT02046044)
- Testing
- Digoxin, Ivabradine
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Kocaeli University
Chronic Heart Failure With Reduced Ejection Fraction
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
This is an observational study in which data already collected from people treated with vericiguat are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- ROVER (NCT06486844)
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Bayer
Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction
Resistance Training in Cardiovascular Disease Patients
In this study coronary artery disease patients and patients with heart failure will be randomly assigned to three training groups: combined aerobic interval training with high intensity resistance training, combined aerobic…
- Trial name
- RT in CVD (NCT04638764)
- Testing
- Aerobic interval training combined with high intensity resistance training, Aerobic interval training combined with low intensity resistance training, Aerobic interval training
- Where
- Slovenia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- General Hospital Murska Sobota
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication
This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Heart Conduction Disorder
- Trial name
- ESCPAND (NCT06278844)
- Testing
- Conduction system pacing, Right ventricular apical pacing
- Where
- Belgium
- Volunteers
- 75 people
- Sponsor
- University Hospital, Antwerp
Atrial Fibrillation (AF), Hart Failure
Heart Failure Biomarkers
Systemic inflammation is closely associated with the development and progression of heart failure (HF). The study assessed the fibrin/albumin (FAR) ratio, a very important biomarker, as a prognostic indicator of HE.
- Trial name
- BIOHF (NCT06616038)
- Testing
- Data collection
- Where
- 2 sites in Italy
- Volunteers
- 114 people
- Sponsor
- I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
Developing Oral LT3 Therapy for Heart Failure - HFrEF
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with reduced ejection fraction (HFrEF) and low triiodothyronine (T3) syndrome…
- Trial name
- DOT3HF-HFrEF (NCT04112316)
- Testing
- Liothyronine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction (HFrEF and HFmrEF)
Polypharmacy, Safety, and Medication Adherence in Patients With Chronic Heart Failure With Reduced and Mildly Reduced Ejection Fraction
This prospective registry study (FARAON) aims to assess the prevalence, structure, safety profile, and dynamics of polypharmacy, as well as its association with medication adherence, quality of life, and clinical outcomes in…
- Trial name
- FARAON (NCT07640854)
- Where
- Russia
- Volunteers
- 130 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease
Assessment of Biomarkers in Patients With Decompensated Heart Failure and Underlying Coronary Artery Disease
Assessment of Biomarkers in Patients with Decompensated Heart Failure and Underlying Coronary Artery Disease
- Trial name
- NCT03551756
- Testing
- Biomarker Assessment
- Where
- 3 sites in United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- CirQuest Labs, LLC